The Briscoe Law Firm, PLLC, founded by a former state prosecutor and enforcement attorney for the United States Securities and Exchange Commission, and the law firm of Cash Powers Taylor, LLP are investigating potential legal claims against the Board of Directors of Micrus Endovascular Corporation (“Micrus”) (NASDAQ: MEND) relating to the proposed acquisition by Johnson & Johnson (NYSE: JNJ).

The agreement, which was announced on July 12, 2010, involves an all-cash transaction valued at approximately $480 million under which Micrus shareholders will receive $23.40 in cash for each Micrus share of common stock they own. For the year ending March 31, 2010, Micrus reported total revenue of $91.090 million and net income of $11.530 million, compared to total revenue and a net loss of $78.196 million and $11.054 million, respectively, for the prior year. As recently as February 19, 2010, Micrus shares trades at $22.24, and at least one analyst set a price target for Micrus stock at $25.00 per share. The investigation relates to possible breaches of fiduciary duty and other violations of state law by the Board of Directors of Micrus for approving this transaction, whether the consideration to be received by Micrus shareholders is fair, and whether Micrus’ Board of Directors acted in the shareholders’ best interests.

If you currently own shares of Micrus and would like additional information regarding this investigation, or if you have information regarding the allegations involving this transaction, please contact Patrick Powers at Cash Powers Taylor, LLP, toll free (877) 728-9607, via e-mail at patrick@cptlawfirm.com, or The Briscoe Law Firm at (214) 706-9314, or via email at WBriscoe@TheBriscoeLawFirm.com. There is no cost or fee to you.

The Briscoe Law Firm is a full service business litigation, commercial transaction, and public advocacy firm with more than 20 years of experience in complex litigation and transactional matters.

Cash Powers Taylor, LLP is a boutique litigation law firm that handles a variety of complex business litigation matters, including claims of investor and stockholder fraud, shareholder oppression, shareholder derivative suits, and security class actions.

Micrus Endovascular (MM) (NASDAQ:MEND)
Gráfico Histórico do Ativo
De Abr 2024 até Mai 2024 Click aqui para mais gráficos Micrus Endovascular (MM).
Micrus Endovascular (MM) (NASDAQ:MEND)
Gráfico Histórico do Ativo
De Mai 2023 até Mai 2024 Click aqui para mais gráficos Micrus Endovascular (MM).